Arcus Biosciences ( NYSE: RCUS ) is scheduled to announce Q2 earnings results on Thursday, August 8th, after market close. The consensus EPS Estimate is -$1.39 and the consensus Revenue Estimate is $26.
49M (-8.7% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 2 downward.
Revenue estimates have seen 1 upward revision and 2 downward. More on Arcus Biosciences Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO Gilead, Arcus combo significantly reduces death risk in colorectal cancer Seeking Alpha’s Quant Rating on Arcus Biosciences Historical earnings data for Arcus Biosciences Financial information for Arcus Biosciences.